Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704262 · ClinicalTrials.gov registry record · Phase 2
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00704262 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 33 participants.
The verdict
NCT00704262, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to monitor the effect of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g on the hypothalamic-pituitary-adrenal axis and on the calcium metabolism in patients with psoriasis vulgaris on the face and on the intertriginous areas
Interventions
- DRUG Calcipotriol plus hydrocortisone (LEO 80190)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704262
The ClinicalTrials.gov registry entry for NCT00704262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calcipotriol plus hydrocortisone (LEO 80190) is the first listed.
NCT00704262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704262 about?
NCT00704262 is a clinical study titled "Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds". There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to monitor the effect of once daily treatment for up to 8 weeks of ...
What is the current status of trial NCT00704262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2008-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00704262?
The interventions under investigation include: Calcipotriol plus hydrocortisone (LEO 80190) (DRUG).
Who is sponsoring clinical trial NCT00704262?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.